. 2020 May 4;10:7404. doi: 10.1038/s41598-020-64285-w

Table 3.

Comparison of quantitative variables between benign and malignant groups.

Variable	Status	No. of patients	Mean ± SD	p-value	No. of Missing	Min _ Max
T2 Map^*	B	68	66.78 ± 10.94	0.001⁺	17	47 _ 105
T2 Map^*	M	20	93.15 ± 7.14
T2 Scaled Ratio^*	B	84	0.19 ± 0.18	0.0001⁺	1	−0.18 _ 1.01
T2 Scaled Ratio^*	M	20	0.66 ± 0.21
Tumor/Myometrium Ratio on T2^*	B	82	−0.02 ± 0.61	0.0001⁺	4	−0.99 _ 2.19
Tumor/Myometrium Ratio on T2^*	M	19	1.12 ± 0.55
Tumor/Psoas Ratio on T2^*	B	84	0.85 ± 1.02	0.0001⁺	0	−0.61 _ 5.48
Tumor/Psoas Ratio on T2^*	M	21	3.19 ± 1.23
Tumor/Myometrium Ratio on CE^*	B	82	0.00 ± 0.39	0.0001⁺	4	−0.75 _ 1.49
Tumor/Myometrium Ratio on CE^*	M	19	0.61 ± 0.33
Tumor/Psoas Ratio on CE ^*	B	84	1.00 ± 0.44	0.0001⁺	0	−0.14 _ 2.97
Tumor/Psoas Ratio on CE ^*	M	21	1.68 ± 0.58
ADC mean*	B	80	1.426 ± 0.233	0.0001⁺	4	0.57 _ 2.37
ADC mean*	M	21	0.877 ± 0.384

⁺Two independent samples t-test; *indicates a variable that led to a p<0.001; B: benign; M: malignant; Min: Minimum; Max: Maximum; SD: standard deviation; No.: number; CE: Contrast Enhanced images.